Harnessing cytokine function to treat cancer has been challenging. In this #FirstDisclosure, cellular engineering is used to generate a new therapy, SENTI-101, showing selective tumor-homing and yields localized & sustained cytokine production. https:/
Data from #preclinical development of SENTI-101, a cell prep of mesenchymal stromal cells expressing IL-12 and IL-21, warrants clinical development for patients with peritoneal #carcinomatosis and high-grade ovarian cancer. https://t.co/NdDVyMHcnm. https:/
275 #CancerImmunology SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express #IL12 and #IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors https://t.co/6d0PMlyFWa
RT @MCT_AACR: Data from #preclinical development of SENTI-101, a cell prep of mesenchymal stromal cells expressing IL-12 and IL-21, warrant…
RT @MCT_AACR: Data from #preclinical development of SENTI-101, a cell prep of mesenchymal stromal cells expressing IL-12 and IL-21, warrant…
RT @MCT_AACR: Data from #preclinical development of SENTI-101, a cell prep of mesenchymal stromal cells expressing IL-12 and IL-21, warrant…
Data from #preclinical development of SENTI-101, a cell prep of mesenchymal stromal cells expressing IL-12 and IL-21, warrants clinical development for patients with peritoneal #carcinomatosis and high-grade ovarian cancer. https://t.co/WBOvlMnSbg. #FirstD
RT @MCT_AACR: Data from #preclinical development of SENTI-101, a cell preparation of mesenchymal stromal cells expressing IL-12 and IL-21,…
RT @MCT_AACR: Data from #preclinical development of SENTI-101, a cell preparation of mesenchymal stromal cells expressing IL-12 and IL-21,…
RT @MCT_AACR: Data from #preclinical development of SENTI-101, a cell preparation of mesenchymal stromal cells expressing IL-12 and IL-21,…
RT @MCT_AACR: Data from #preclinical development of SENTI-101, a cell preparation of mesenchymal stromal cells expressing IL-12 and IL-21,…
Data from #preclinical development of SENTI-101, a cell preparation of mesenchymal stromal cells expressing IL-12 and IL-21, warrants clinical development for patients with peritoneal #carcinomatosis and high-grade ovarian cancer. https://t.co/um4Kk2q8MA.
Data from #preclinical development of SENTI-101, a cell preparation of mesenchymal stromal cells expressing IL-12 and IL-21, warrants clinical development for patients with peritoneal #carcinomatosis and high-grade ovarian cancer. https://t.co/V1ZwX18HEX #
One nemesis of cancer is Senti Biosciences' SENTI-101, an hMSC grown from RoosterBio cellular starting materials. We are delighted to support this therapy and help advance synthetic biology efforts to “program” MSCs via new products such as RoosterGEM. htt
First Disclosure! Data from #preclinical development of SENTI-101, a cell preparation of mesenchymal stromal cells expressing IL-12 and IL-21, warrants clinical development for patients with peritoneal #carcinomatosis and high-grade ovarian cancer. https:/